Skip to main content

Table 1 Poliovirus-antibody seropositive subjects according to sex, age, and region (n= 745)

From: A national cross-sectional study for poliovirus seroprevalence in the Republic of Korea in 2012: implication for deficiency in immunity to polio among middle-aged people

   PV1 PV2 PV3
No. of tested samples (%) No. of positive samples (%) P value* No. of positive samples (%) P value No. of positive samples (%) P value
Total 745 616 (82.7)   685 (91.9)   509 (68.3)  
Sex        
  Male 349 (46.8) 289 (82.8) 0.51 314 (90.0) 0.04 236 (67.6) 0.38
  Female 396 (53.2) 327 (82.6)   371 (93.7)   273 (68.9)  
Age (years)        
  6–10 (IPV) 236 (31.7) 220 (93.2) <0.01 228 (96.6) <0.05 207 (87.7) <0.01
  11–20 (OPV) 216 (29.0) 173 (80.1)   199 (92.1)   126 (58.3)  
  21–40 (OPV) 135 (18.1) 106 (78.5)   122 (90.4)   72 (53.3)  
  41–60 (OPV) 113 (15.2) 79 (69.9)   95 (84.1)   74 (65.5)  
  >60 (OPV) 45 (6.0) 38 (84.4)   41 (91.1)   30 (66.7)  
Region        
  Gyeonggi-do 237 (31.8) 202 (85.2) 0.065 226 (95.4) 0.018 172 (72.6) 0.033
  Gyeongsang-do 170 (22.8) 135 (79.4)   154 (90.6)   108 (63.5)  
  Seoul 126 (16.9) 103 (81.7)   114 (90.5)   80 (63.5)  
  Chungcheong-do 112 (15.0) 95 (84.8)   101 (90.2)   85 (75.9)  
  Jeolla-do 68 (9.1) 54 (79.4)   59 (86.8)   42 (61.8)  
  Gangwon-do 24 (3.2) 19 (79.2)   23 (95.8)   17 (70.8)  
  Jeju-do 8 (1.1) 8 (100.0)   8 (100.0)   5 (62.5)  
  1. *P < 0.05 indicates significant differences of seroprevalence among the compared groups.
  2. IPV, inactivated poliovirus vaccine; OPV, oral poliovirus vaccine; PV, poliovirus.